can anyone use semaglutide GLP-1s What to Know About Semaglutide:

Novo Nordisk is awaiting an FDA decision for their fixed-dose combination of the amylin receptor agonist, cagrilintide, and the GLP-1, semaglutide

Key Things We Consider Initial metabolic levels and body composition Previous use of appetite-related medications Sensitivity to digestion changes when starting treatment Weekly appetite shifts Goals for the long run and when to expect results Starting with smaller doses helps the body adapt over time

Most doctors are glad to add this when you mention the concern

Unknown Long-Term Effects: The absence of longitudinal human clinical trial data means that long-term safety outcomes from sustained BPC-157 use are not established

Buying them is a legal gray area: selling them for human use violates FDA rules, the products are not quality-controlled, and vendors have received FDA warning letters